# A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)

> **NCT07496567** · PHASE2,PHASE3 · RECRUITING · sponsor: **EyeBiotech Ltd.** · enrollment: 960 (estimated)

## Conditions studied

- Macular Degeneration
- Age-Related Macular Degeneration
- Choroidal Neovascularization
- Wet Macular Degeneration

## Interventions

- **DRUG:** Tiespectus
- **DRUG:** Aflibercept

## Key facts

- **NCT ID:** NCT07496567
- **Lead sponsor:** EyeBiotech Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-15
- **Primary completion:** 2028-07-31
- **Final completion:** 2028-07-31
- **Target enrollment:** 960 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07496567

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07496567, "A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07496567. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*